Cancer Vaccine

Vaccine effective against melanoma in mice

Published in Gene Therapy Weekly, November 14th, 2002

by Maria G. Essig, MS, ELS, senior medical writer - Immunization with a vaccine containing mouse fibroblasts transfected with DNA from B16 mouse melanoma cells that expressed syngeneic and allogeneic major histocompatibility complex (MHC) class I determinants significantly increased survival in mice with malignant melanoma.

"Most neoplasms do not induce antitumor immune responses that can control tumor growth," explained Edward De Zoeten and colleagues at the University of Illinois in Chicago. "Tumor associated antigens (TAAs) are insufficiently immunogenic. We hypothesized that the immunogenic properties of 'weak' TAAs formed by the neoplasm would be enhanced if they...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry